Last reviewed · How we verify
BIIB037
At a glance
| Generic name | BIIB037 |
|---|---|
| Also known as | Aducanumab, fully human IgG1 anti-Aβ mAb |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy (EARLY_PHASE1)
- A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (PHASE3)
- A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (PHASE3)
- A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) (PHASE3)
- An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
- A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers (PHASE1)
- A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers (PHASE1)
- A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |